Nos idées

I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across Canada and in a focused group of comparator jurisdictions.

Thérapies CAR-T

Une étude de cas rétrospective sur une nouvelle immunothérapie

 

Lire la suite

LUXTURNA

Une étude de cas rétrospective sur une thérapie génique spécialisée

 

Lire la suite

LEQEMBI

Une étude de cas prospective sur un nouveau médicament contre la maladie d'Alzheimer

Lire la suite

CRISPR

A snapshot case study on CRISPR/Cas9 Technology for Blood Disorders

 

Lire la suite

Looking across these case studies, I2U identified 7 distinct implementation challenges each with the potential to diminish the optimal patient and system impact of a given breakthrough medicine:

Recent Webinars

January 17, 2025

Helping Health Systems Better Prepare for Breakthrough Medicines: Profiling an Innovative New Tool

https://www.youtube.com/watch?v=kAy_08AXbVg

June 1, 2023

Maximizing the Uptake of Breakthrough Medicines Across Canada: Lessons from CAR-T
https://www.youtube.com/watch?v=qd_64OqEOpI